Introduction
Gastroesophageal reflux is defined as the passage of gastric contents into the esophagus; it occurs in healthy infants, children, and adults. 1 By contrast, gastroesophageal reflux disease (GERD) comprises the complications and symptoms that can result from reflux of gastric contents into the esophagus or oropharynx. 1 Regurgitation is the passage of refluxed gastric contents into the oropharynx, and vomiting is the expulsion of refluxed gastric contents from the mouth. 1 GERD is among the five most prevalent and costly gastrointestinal (GI) and liver diseases in the United States, with 18.6 million cases and direct costs amounting to $10 billion each year. 2 GERD has a substantial negative impact on quality of life and sense of well-being in adults, and it can result in workplace absences and reduced productivity. 3, 4 Unfortunately, no large multicenter or cohort studies of the impact of GERD on quality of life have been conducted in pediatric patients. Validated symptom assessment instruments with quality-of-life endpoints are needed for use in large, multicenter trials to assess the impact of GERD in pediatric patients.
Prevalence and Natural History
In the past, it was commonly accepted that infants outgrow problems with gastroesophageal reflux around the time they are 3 months of age. However, a cross-sectional analysis revealed that regurgitation typically persists for the first 6 months of life, after which time the prevalence decreases markedly. 5 Most infants outgrow the problem by the time they reach 1 year of age. 5 GERD is particularly common in premature infants. More than 85% of premature infants evaluated using esophageal pH monitoring had evidence of GERD, including 3% to 10% with apnea, bradycardia, or exacerbation of bronchopulmonary dysplasia. 6 These premature infants often have a history of prolonged ventilator use and chronic lung damage and are at risk for complications from GERD.
Estimates of the prevalence of GERD in infants less than 3 months of age vary widely, from 20% to 100%. 6 Almost all infants in this age group experience regurgitation or reflux, although the percentage with disease symptoms is unclear. About one third of infants with symptoms receive medical attention. 6 In most patients (80%), symptoms resolve with minimal intervention, without diagnostic evaluation or long-term follow up. 6 GERD has been observed in 20% to 40% of children 6 months of age or younger using patient histories or esophageal pH monitoring, and in 10% to 20% of children 12 months of age based on patient histories. 6 Abdominal pain was a common complaint in a crosssectional survey of parents of 3-to 9-year-olds, with 23.9% of parents reporting the symptom in their child. 7 Whether this complaint reflects GERD or some other problem is unclear. Regurgitation was reported by 8.2% of children 10 to 17 years of age when a validated symptom survey instrument was used. 7 The prevalence of heartburn increases with age, from 1.8% in 3-to 9-year-olds to 3.5% in 10-to 17-year-olds. 7 Reporting by parents may underestimate the prevalence of heartburn, so it is important that the patient be interviewed directly about symptoms. The prevalence of heartburn is higher in adults than in children; nearly 20% of adults experience heartburn or acid regurgitation at least weekly. 8 A case-control study found that 21% to 29% of adults with reflux recalled having symptoms (e.g., heartburn, dysphagia) during childhood. 9 Thus, gastroesophageal reflux may be a lifelong problem that begins in childhood and is followed by alternating periods of wellness and symptoms.
Data from the Pediatric Health Information Survey, a database of health information from patients at 37 children's hospitals in the United States, revealed that GERD was one of the top three discharge diagnoses, accounting for 3.5% of all hospital discharges. 10 Male children were significantly more likely to be hospitalized with GERD and to have more complicated disease than female children. 10 The costs for managing GERD in hospitalized children amounted to more than $700 million in 2000. 10 A study of the rate of diagnosis of GERD in hospitalized infants in a single U.S. Army hospital found a 20-fold increase over the 25-year period from 1971 to 1995. 11 This increase may reflect an increase in GERD prevalence, an increase in awareness of the condition, or both. GERD in pediatric patients who are ambulatory also appears to be increasing and represents a public health concern. 6, 12 However, there currently are no surveillance systems or large multicenter ambulatory care databases to monitor epidemiologic patterns in this population.
Pathophysiology
GERD is attributed to abnormalities in the lower esophageal sphincter (LES). The LES normally prevents the reflux of gastric contents, although it relaxes briefly during swallowing to permit the passage of food and liquids from the esophagus into the stomach. 13 Prolonged or frequent transient relaxation of the LES is a common cause of gastroesophageal reflux. 1 Reflux can occur when the intragastric or intraabdominal pressure exceeds the LES pressure.
1 Consuming large meals and wearing tight clothing increase intragastric pressure and the likelihood of reflux. 13 A recumbent body position negates the effect of gravity to promote esophageal clearance. Diet (e.g., chocolate, coffee or caffeine, fatty foods) and exposure to tobacco smoke and alcohol may contribute to gastroesophageal reflux. 1, 13 Other factors that cause or contribute to GERD include highly acidic gastric contents, delayed gastric emptying, and abnormalities in physiologic mechanisms for clearing the esophagus (e.g., peristalsis) and protecting the esophageal mucosa (i.e., the mucosal barrier) when reflux occurs (e.g., esophageal motility abnormalities). 1 Obesity may be an independent risk factor for GERD in adults, but its associated with GERD in children warrants further study.
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Complications
Chronic and frequent reflux of highly acidic gastric material can lead to esophagitis and esophageal strictures. Approximately 10% to 15% of adults undergoing upper endoscopy for heartburn have evidence of erosive esophagitis.
14 Erosive esophagitis is found in fewer than 10% of infants and children who are thriving and have no comorbid conditions. 1, 6 However, infants and children with neurologic impairment or injury (e.g., cerebral palsy) are at increased risk for GERD complications; erosive esophagitis is present in 30% to 70% of these patients. 1, 6 Barrett's esophagus, which is characterized by the replacement of the normal distal esophageal mucosa (squamous epithelium) with metaplastic intestinal-type epithelium that may become malignant, is a potential complication of GERD. Data from the Pediatric Health Information Survey suggest that the incidence of Barrett's esophagus has nearly doubled in the United States in recent years, from less than 2% of hospitalized children in 1997 to 3.8% in 2000. 10 Whether the increased incidence of childhood Barrett's esophagus is the result of increased awareness and diagnosis or a true increase in disease incidence requires further study.
Esophageal adenocarcinoma has been strongly linked to the duration, frequency, and severity of heartburn symptoms in adults. 15 Also, the Pediatric Health Information Survey revealed that the prevalence of esophageal adenocarcinoma increased in pediatric patients to nearly 1% in 2000. 10 Esophageal dysplasia (a precursor to adenocarcinoma) was observed primarily in children with neurologic injury or congenital abnormalities of the esophagus.
Extra-esophageal manifestations of GERD may include a number of conditions, including chronic cough or sore throat, hoarseness, wheezing, asthma, apnea, bradycardia, dental erosions, halitosis, laryngitis, sinusitis, pharyngitis, and otitis media. Two mechanisms have been proposed for extra-esophageal symptoms of GERD: (1) direct exposure to gastric contents refluxed beyond the esophagus (e.g., aspiration into the airways) and (2) indirect effects via common neural pathways between the lower esophagus and the respiratory tract. Esophageal acidification can result in respiratory smooth muscle hyperresponsiveness, inflammation, and hypertrophy because of the common innervation of the respiratory tract and esophagus. 1 An acute life-threatening episode (ALTE) is a frightening incident in infancy or early childhood and is characterized by apnea, changes in skin color (e.g., cyanosis, pallor) and muscle tone (e.g., body stiffness or limpness), and choking or gagging that requires intervention by the caregiver. 1 Possible causes include GERD, a cardiac or central nervous system (CNS) disorder (CNS immaturity is a common cause of apnea and bradycardia in premature infants and neonates), infection, and upper airway obstruction (e.g., intentional suffocation, inadvertent airway blockage by the excessively large tongue in patients with Down syndrome). 1 In patients with ALTEs, the prevalence of recurrent regurgitation or emesis is 60% to 70% and abnormal esophageal pH values are found in 40% to 80% of patients monitored. 1 The evidence for a causative role of gastroesophageal reflux in apnea is equivocal and requires further study. 16, 17 The strongest relationship between gastroesophageal reflux and obstructive or mixed apnea was demonstrated in infants who had episodes while they were awake and supine, usually within 1 hour after a feeding. 1 Estimates of the prevalence of gastroesophageal reflux in children with pulmonary disease range from 47% to 64%. [18] [19] [20] [21] [22] [23] [24] Data from the Pediatric Health Information Survey suggest that more than 25% of children hospitalized with GERD have either acute or chronic respiratory disease. 10 Whether gastroesophageal reflux is the cause or result of asthma and other respiratory illnesses is unclear. Results of esophageal pH studies are abnormal in 61% children with persistent asthma, although approximately half of these patients have no or minimal symptoms. 1 The relationship between nocturnal gastroesophageal reflux and asthma is controversial in both adults and children. The evidence of a relationship is weaker in children than in adults because of the lack of well-designed studies in pediatric patients. In a study of adults, there was significantly more acid reflux during sleep in patients with asthma than in patients without asthma. 25 In children with asthma and gastroesophageal reflux, acid infusion into the distal esophagus at night in an experimental setting was associated with bronchoconstriction and wheezing. 26 Antireflux therapy in 168 children with asthma produced clinical improvement or reduced the dosage of bronchodilator and anti-inflammatory medication in 63% of patients. 1 Data from adults with asthma suggest that at least 3 months of antireflux therapy is needed for improvement in respiratory symptoms. 
Diagnosis
The diagnostic work-up for an infant or child with suspected GERD depends on the age of the patient and the presenting signs and symptoms. 1 The North American Society for Pediatric Gastroenterology, Hepatology and Nutrition recently developed evidence-based clinical practice guidelines with algorithms for the evaluation and treatment of gastroesophageal reflux in infants and children (Figures 1-5) .
A history and physical examination are sufficient for the diagnosis of gastroesophageal reflux and detection of complications in most infants with recurrent vomiting and • Consultation with Pediatric GI • EGD + biopsy most older children with regurgitation and heartburn. 1 Warning signs of more serious underlying disease in an infant with recurrent vomiting include bilious or forceful vomiting, hematemesis, diarrhea, constipation, fever, lethargy, seizures, abdominal tenderness or distention, and failure to thrive. 1 An upper GI series (i.e., the use of swallowed barium as a contrast medium for radiographic examination) is not sufficiently sensitive or specific for the definitive diagnosis of reflux (false positive and false negative test results are common).
1 However, it is useful for detecting anatomic abnormalities (e.g., intestinal malrotation), hiatal hernia (displacement of the uppermost part of the stomach upward through the diaphragm), and esophageal strictures in a child with recurrent regurgitation or vomiting. 1 Esophageal pH monitoring is a reliable method for detecting acid reflux. 1 It involves insertion of a probe with a microelectrode through the nose into the esophagus to measure intraluminal pH. The frequency and duration of acid reflux episodes are recorded on a continuous basis using a small device about the size of a portable electronic game or audio cassette player. Symptoms can be temporally linked with acid reflux episodes if a diary of the timing of symptoms is maintained. Esophageal pH monitoring also allows assessment of the adequacy of esophageal clearance mechanisms and treatment. 1 However, esophageal pH monitoring does not detect reflux that is nonacidic (e.g., postprandial reflux in infants), measure the volume of refluxed fluid or fluid shifts in the esophagus, or detect GERD complications (e.g., respiratory problems) that develop despite normal acid reflux. 1 The usefulness of esophageal pH monitoring in infants with apnea or ALTEs has not been demonstrated. 1 Heart rate, chest wall movement, nasal airflow, and oxygen saturation must be recorded simultaneously for esophageal pH monitoring to provide meaningful information in patients with ALTEs. 1 This usually is accomplished in a sleep study with pH probe combined or done concurrently.
Sequential 24-hour esophageal pH monitoring allows the identification of nocturnal reflux and quantification of the percentage of time in a 24-hour period with an acidic esophageal pH (i.e., a pH less than 4). In adults, this percentage normally is approximately 2%. 1 However, normal values are up to 12% in the first year of life and up to 6% thereafter. 1 The symptom index is the ratio of the number of episodes of a particular symptom occurring during episodes of acid reflux to the total number of episodes of that symptom. In adults, a symptom index of 0.5 or greater for heartburn suggests that heartburn is the result of reflux. 1 Endoscopy and biopsy of the esophageal mucosa can be used to verify the presence or absence of reflux esophagitis, Barrett's esophagus, esophageal strictures, eosinophilic esophagitis (a form that appears to have an allergic component that may explain the failure of acid-suppressant therapy), and esophagitis from other causes (e.g., Crohn's disease, infection). 1 Biopsy typically is performed during endoscopy in pediatric patients regardless of whether the mucosa appears visibly abnormal to the endoscopist, because histopathologic changes to the mucosa often are subtle in pediatric patients. Manifestation of disease in pediatric patients is subtle. The oropharynx and upper pharynx should be examined during endoscopy because of the possibility of involvement of these areas (e.g., vocal cord inflammation) in patients with GERD.
Management
The goals of treatment for GERD include elimination of symptoms, healing of esophagitis, prevention or management of complications, and maintenance of remission. Therapeutic options include lifestyle changes (e.g., dietary modification, proper body positioning during and after feeding or eating), pharmacologic therapy, and antireflux surgery. Educating the parents or caregivers (e.g., about warning signs of a serious condition in an infant with Other abnormalities:
• recurrent vomiting) and providing reassurance as appropriate (e.g., for the parents of a "happy spitter," an infant with uncomplicated gastroesophageal reflux) are recommended. 
Lifestyle Changes
Thickening an infant's formula (e.g., by adding rice cereal) may decrease the number of episodes of vomiting. 1, 27, 28 It also may provide additional calories, which is beneficial for infants who are underweight. A hypoallergenic formula may be tried for 1 to 2 weeks in formula-fed infants with vomiting, because some infants have an allergy to proteins in cow's milk. 1 In children and adolescents with gastroesophageal reflux, the impact of dietary modification, avoidance of alcohol and cigarette smoke, and weight loss (for obese patients) is unclear. Nevertheless, avoidance of caffeine, chocolate, and spicy foods is recommended if these substances appear to trigger or be associated with symptoms. 1 Elevating the head of the bed, an intervention recommended for adults with GERD, and positioning the patient on the left side is likely to provide benefit for children with nocturnal gastroesophageal reflux. 1, 13 Infants should be placed in a supine position in their cribs; a prone position increases the risk of sudden infant death syndrome. 1 The use of a portable infant carrier, which can be placed on a table, helps keep the infant's head elevated. However, when an infant is in this type of seat, his or her hips tend to be flexed, which places pressure on the stomach and increases the risk of reflux. Positioning a small pillow at the bottom of the carrier beneath the infant's buttocks helps keep the hips extended and reduces pressure on the stomach and risk for reflux.
Pharmacotherapy
The ideal pharmacologic agent for treating GERD in pediatric patients is one that has well-documented efficacy in this patient population, no adverse effects, a pleasant taste (without an aftertaste) and texture, and a low cost. Cost of drug therapy should take into consideration the costs saved by avoiding hospitalization and surgery as well as the acquisition cost of the drug. The ideal medication should be available in a dosage form that is easy to administer to pediatric patients (i.e., an oral liquid instead of solid oral dosage forms, which are difficult for young children to swallow) and would require only infrequent dosing (e.g., once or twice a day) to avoid the need for doses in daycare and school settings and to promote compliance with the prescribed treatment regimen.
Currently available pharmacologic agents include antacids, mucosal protectants (e.g., sodium alginate, sucralfate), prokinetic agents (e.g., bethanechol, metoclopramide, cisapride, erythromycin), histamine H 2 -receptor antagonists, and proton pump inhibitors. Some but not all of these agents are approved for use in infants and children. The Food and Drug Administration (FDA) allows the extrapolation of drug safety and efficacy data from adults to children if the disease or condition for which the drug is used is similar in children and adults, although some additional safety data must be collected before a drug is approved for pediatric use. GERD is considered sufficiently similar in adults and children as young as 1 year of age. However, FDA does not consider GERD in infants (i.e., patients less than 1 year of age) to be sufficiently similar to GERD in adults. Therefore, extensive efficacy and safety data in infants are required before FDA will approve a drug for the treatment of GERD in this age group. Most drugs have not been used on a long-term basis in pediatric patients, although long-term safety data in adults are available. Antacids and Mucosal Protectants. Antacids neutralize gastric acid, and sodium alginate (an ingredient in some antacid preparations) protects the esophageal mucosa by forming a gel on the surface of the stomach contents and occasionally inhibiting regurgitation.
1 Sucralfate (an aluminum complex of sucrose sulfate) binds to and protects the esophageal mucosa. 29 Evidence of the efficacy of these agents in children with gastroesophageal reflux is equivocal, and none of these agents is approved by FDA for treating GERD. 1 Frequent administration is required, and interactions with other drugs are common. 29, 30 Long-term use of aluminum-containing antacids should be avoided because of the risk of aluminum toxicity, although these agents may be used intermittently for symptomatic relief in older children.
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Prokinetic Agents. Prokinetic agents appear to increase LES pressure, improve esophageal peristalsis, and accelerate gastric emptying. However, whether these agents reduce the frequency of acid reflux remains to be determined. 1 Cisapride is effective for improving symptoms in infants and children with GERD.
1 However, because the drug is associated with serious cardiac arrhythmias in patients with certain risk factors (e.g., receiving certain concomitant medications, congenital heart disease), it is available only on a restricted basis to pediatric patients with refractory GERD (e.g., associated with failure to thrive, asthma, bradycardia, or apnea). 31 Studies demonstrating benefit from the use of other prokinetic agents in pediatric patients with GERD are lacking, and none of the agents is approved by FDA for this indication in children.
1 Histamine H 2 -Receptor Antagonists. Histamine H 2 -receptor antagonists competitively inhibit the action of histamine at histamine H 2 receptors on parietal cells in gastric glands. 32 These agents are highly selective for histamine H 2 receptors and have little or no effect on histamine H 1 receptors. Parietal cells have receptors for histamine, acetylcholine, and gastrin, all of which can elicit a cascade of events that result in hydrochloric acid secretion into the gastric lumen. 33 Histamine H 2 -receptor antagonists inhibit acid secretion elicited by histamine but have no effect on acid secretion caused by acetylcholine or gastrin.
The drugs are rapidly absorbed after oral administration. 32 The effects of histamine H 2 -receptor antagonists on acid secretion are dose-and concentration-dependent. 32 The gradual loss of efficacy with long-term administration is a limitation to the use of histamine H 2 -receptor antagonists. It may be the result of several mechanisms, including stimulation of acetylcholine or gastrin receptors, tachyphylaxis (the loss of efficacy due to a disconnection between receptor stimulation and signaling of activity inside the cell), or down regulation of histamine H 2 receptors. Histamine H 2 -receptor antagonists can decrease the absorption of drugs that require an acidic environment for absorption (e.g., ketoconazole, itraconazole). 32 Cimetidine inhibits cytochrome P-450 enzymes (e.g., 1A2, 2C19, and 3A) and has the potential to interact with other drugs metabolized by these isoenzymes (e.g., phenytoin, proprannolol, theophylline, warfarin). 32 Ranitidine interacts with the cytochrome enzymes in a different manner than does cimetidine and inhibits the metabolism of other drugs only minimally. 35 The other histamine H 2 -receptor antagonists do not inhibit cytochrome enzymes. 36, 37 Table 1 provides information about the oral dosages of histamine H 2 -receptor antagonists in pediatric patients with GERD. The efficacy of cimetidine and nizatidine in treating esophagitis has been demonstrated in randomized, placebocontrolled studies in small numbers of children. 40, 41 In a 12-week, randomized, double-blind study of 32 patients 1 month to 14 years of age with reflux esophagitis, oral cimetidine 30-40 mg/kg/day was significantly more effective than placebo in healing esophagitis and reducing symptoms. 40 In addition, 8 weeks of nizatidine (10 mg/kg/day) was significantly more effective than placebo in healing esophagitis and reducing symptoms and the time during which the esophageal pH was below 4 in 24 patients 6 months to 8 years of age. 41 Ranitidine and famotidine appear to be as effective as cimetidine and nizatidine, although comparative studies are needed. 1 A study of the pharmacokinetics and pharmacodynamics of ranitidine (5 mg/kg) in infants 6 weeks to 6 months of age with gastroesophageal reflux revealed that the esophageal pH paralleled the plasma ranitidine concentration and the intragastric pH remained above 4 for 9 hours after a dose. 42 Feedings raise the esophageal pH above 4 for about 2 hours.
1,28 Therefore, about 11 hours of acid suppression is provided if ranitidine is administered about 2 hours after a feeding, and the use of two daily doses in this manner provides nearly 24 hours of acid suppression.
In pediatric patients 6 months to 13 years of age with esophagitis that was refractory to conventional dosages of ranitidine (8 mg/kg/day), the use of high-dose ranitidine (20 mg/kg/day) reduced symptoms and improved healing. 43 High-dose ranitidine was comparable in efficacy to omeprazole in relieving symptoms and healing esophagitis. Proton Pump Inhibitors. Proton pump inhibitors bind to hydrogen/potassium adenosine triphosphatase (an enzyme system referred to as the "proton pump") in parietal cells, thereby blocking the ion exchange that is the final step in hydrochloric acid secretion. 44 These agents inhibit acid secretion regardless of whether it is stimulated by histamine, acetylcholine, or gastrin. Proton pump inhibitors require activation in the acidic environment of the secretory canaliculi of parietal cells. They are best taken about 30 minutes before meals so that food cannot interfere with absorption and peak plasma drug concentrations coincide with meal-stimulated acid secretion. 44, 45 The drugs are less effective during fasting conditions when acid secretion is lower.
Proton pump inhibitors are inactivated by gastric acid. Therefore, they are formulated with enteric coatings, which allow the drug to pass through the stomach intact and enter the intestine, where the pH is less acidic and the drug is absorbed. Proton pump inhibitors have a short elimination half-life but a long duration of action because binding to the proton pump is irreversible and cessation of pharmacologic activity requires the synthesis of new enzyme. Proton pump inhibitors do not affect gastric motility or secretion of other gastric enzymes.
Proton pump inhibitors can interact with drugs that require an acidic environment for absorption (e.g., ketoconazole, itraconazole). 46 Proton pump inhibitors are metabolized by cytochrome P-450 2C19 and 3A4 to varying extents and could interact with other drugs that are metabolized by these enzymes. 46 Omeprazole inhibits the metabolism of diazepam, warfarin, and phenytoin. 46, 47 The other proton pump inhibitors do not appear to inhibit the metabolism of other drugs by cytochrome P-450 enzymes to a clinically significant extent in adults. 46 However, the cytochrome enzymes that metabolize proton pump inhibitors may be deficient in neonates; enzyme activity, drug disposition, and risk for drug interactions may change with increases in age and the accompanying ontogeny (i.e., development and maturation) of physiologic processes during infancy and the child's growth and maturation.
Omeprazole and lansoprazole are the only two proton pump inhibitors currently approved by FDA for use in pediatric patients (Table 2 ). Both omeprazole and lansoprazole are available as capsules containing entericcoated granules. 45, 47 Lansoprazole also is available as packets of granules for use in preparing an oral suspension and as orally disintegrating tablets containing enteric-coated microgranules, both of which have delayed-release properties. 45 The orally disintegrating tablets should not be chewed or swallowed intact, which may limit their use in young children. Esomeprazole (the S isomer of omeprazole) is available as capsules containing enteric-coated pellets, and rabeprazole and pantoprazole are available as enteric-coated tablets. An injectable form of pantoprazole also is available, and an oral liquid dosage form currently is under investigation. Pantoprazole, rabeprazole, and esomeprazole are not approved by FDA for use in pediatric patients, although clinical trials in this patient population are under way.
The contents of omeprazole and lansoprazole capsules may be sprinkled in slightly acidic fruit juice (e.g., apple, orange), applesauce, or yogurt immediately before administration. 45, 47 The contents of lansoprazole packets should be mixed only with water. Chewing omeprazole and lansoprazole granules should be avoided because it causes a bitter taste and disrupts the delayed-release characteristics of the enteric coating. 49 The contents of omeprazole delayed-release capsules (pellets) may be added to applesauce that is not hot immediately before administration. A glass of cool water should be swallowed after administration of the dose. The pellets should not be chewed or crushed. b The contents of a 20-mg omeprazole capsule or a 30-mg lansoprazole capsule may be mixed with 10 mL of sodium bicarbonate 8.4% to produce a 2-mg/mL or 3-mg/mL simplified omeprazole or lansoprazole suspension, respectively, for administration through a gastric, jejunal, or duodenal tube. These suspensions have an unpleasant taste when they are administered orally. c The contents of lansoprazole delayed-release capsules may be mixed with applesauce, yogurt, strained pears, cottage cheese, Ensure pudding, or apple, orange, or tomato juice. The contents of lansoprazole packets should be mixed with only water.
Many children with GERD have neurologic impairment and require feeding tubes for nutritional support. Mixtures of granules may be difficult to administer through tubes with a narrow bore (e.g., a duodenal or jejunal tube) and gastric tubes with right-angle connectors because of clogging (the use of a gastric tube with a straight-angle connector is preferred over one with a right-angle connector). Mixing the contents of a 20-mg omeprazole capsule or a 30-mg lansoprazole capsule with 10 mL of sodium bicarbonate 8.4% to produce a 2-mg/mL or 3-mg/mL simplified omeprazole or lansoprazole suspension, respectively, is preferred for such patients. 48 The use of sodium bicarbonate permits the dissolution of the enteric coating on the granules, which are designed to dissolve in the alkaline environment of the small intestine. The drugs are not stable in aqueous solutions and must be administered immediately when mixed with water or slightly acidic juices. The 2-mg/ mL simplified omeprazole suspension was stable in ambercolored oral syringes for 14 days at room temperature and 45 days under refrigeration. 48 The 3-mg/mL simplified lansoprazole suspension was stable for 8 hours at room temperature and 14 days under refrigeration in ambercolored oral syringes. 48 In a stock bottle, simplified omeprazole suspension was stable for 14 days at room temperature and up to 30 days under refrigeration. 50 Simplified suspensions are less suitable for oral administration than for administration through a feeding tube because they have an unpleasant taste.
Proton pump inhibitors are more effective than histamine H 2 -receptor antagonists in reducing acid secretion, relieving GERD symptoms, and healing esophagitis.
1 Proton pump inhibitors also are more effective than histamine H 2 -receptor antagonists in maintaining remission. Omeprazole. In studies of pediatric patients with esophagitis that was resistant to histamine H 2 -receptor antagonists, omeprazole was effective in improving symptoms and healing esophagitis.
43, 51, 52 Eight weeks of treatment with omeprazole 40 mg/day/1.73 m 2 body surface area or highdose ranitidine (20 mg/kg/day) reduced esophageal acid exposure and symptoms and promoted healing in 25 infants and children 6 months to 13 years of age with severe reflux esophagitis despite prior treatment with conventional dosages of ranitidine (8 mg/kg/day). 43 In a study of pediatric patients 3-18 years of age with refractory reflux esophagitis or peptic ulcer, omeprazole (0.3-0.7 mg/kg/day) provided greater acid suppression than did histamine H 2 -receptor antagonists or placebo. 53 In 12 infants with esophagitis that had failed to respond to a regimen of cimetidine, cisapride, an antacid containing sodium alginate, and changes in body positioning, omeprazole 0.5 mg/kg once daily for 6 weeks reduced intragastric acidity and symptoms. 51 Healing of esophagitis was demonstrated by endoscopy in 9 of the 12 patients. 51 Similar results were found in another study of 10 children 25-109 months of age with severe esophagitis who received omeprazole 20 mg or 40 mg once daily (the larger dosage was used for patients weighing more than 30 kg and the smaller dosage was given to patients weighing less than 30 kg) for 3 months. 52 Twenty-four-hour esophageal pH monitoring revealed that the number of postprandial reflux episodes decreased from 36 to 8.5. Six of the 10 patients experienced a relapse after discontinuation of omeprazole. 52 Relapse after discontinuation of omeprazole therapy has been reported in other studies of pediatric patients. 54, 55 The dosages of omeprazole required for healing of chronic, severe esophagitis in pediatric patients (0.7-3.5 mg/ kg/day) are higher on a milligram-per-kilogram basis than those required for adults. 56 In a study of 115 infants (0.7-21.8 months of age) receiving omeprazole 0.5, 1, or 1.5 mg/kg/day for 8 weeks, the time to onset of symptom relief was shorter with the larger dosages than with the smaller dosages.
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Lansoprazole. The efficacy of lansoprazole in reducing GERD symptoms and healing esophagitis was demonstrated in an uncontrolled, open-label study of 66 patients 1 to 11 years of age with GERD, including 27 patients with erosive esophagitis. 45 There was a reduction in the frequency and severity of symptoms of approximately 50% after 8-12 weeks of treatment with lansoprazole 15 mg/day or 30 mg/ day as a single daily dose (the smaller dosage was given to patients weighing 30 kg or less, and the larger dosage was used for patients weighing more than 30 kg). Some patients required an increase in dosage (up to 30 mg twice daily) if symptoms persisted after 2 weeks of treatment. Endoscopic healing of erosive esophagitis was demonstrated in 21 of 27 patients after 8 weeks of treatment and in all 27 patients after 12 weeks of treatment. 45 In a study of 35 children 3-15 years of age with esophagitis refractory to histamine H 2 -receptor antagonists, 12 weeks of lansoprazole 1.3-1.5 mg/kg/day was more effective in improving symptoms and healing esophagitis than 0.8-1.0 mg/kg/day. 58 The healing rate was 75% and 35% with the larger and smaller dosage, respectively. 58 In 23 patients 4 months to 13 years of age with reflux esophagitis, 9 (39%) of patients responded to treatment with lansoprazole 0.73 mg/kg/day for 7 days (response was defined as an esophageal pH less than 3 for more than 65% of a 24-hour period). 59 An additional six patients responded only after the dosage was increased to 1.44 mg/kg/day for the subsequent 7 days (i.e., a total of 15 of the 23 patients responded). Healing of esophagitis was documented in 12 (80%) of 15 evaluated patients. 59 An open study of children 18 days to 14 years of age with gastric acid-related disorders was conducted to collect pharmacokinetic and pharmacodynamic data after administering lansoprazole as single 17-mg/m 2 doses and multiple 17-mg/m 2 doses for 7-14 days. 60 Multiple doses provided greater acid suppression than did single doses; the percentages of time in a 24-hour period with the intragastric pH less than 4 and less than 3 were lower after multiple doses than after a single dose. The pH was less than 4 during 61% of a 24-hour period after a single lansoprazole dose and during 47% of a 24-hour period after multiple doses. The lansoprazole peak plasma concentration, elimination halflife, and area under the plasma concentration-time curve (AUC) were higher and the clearance and volume of distribution were lower after single doses than after multiple doses. An analysis of single-and multiple-dose lansoprazole pharmacokinetic data grouped by age revealed that the elimination half-life decreased with age from infancy throughout childhood, reaching adult levels in late childhood. Clearance was relatively low in neonates (i.e., during the first month of life). Clearance and volume of distribution in children 2-24 months of age were increased beyond levels in the neonatal period and declined thereafter. The AUC was high in the neonatal period and declined dramatically after the age of 24 months. The antisecretory effect of the drug appeared to decrease along with decreases in AUC. These findings may reflect ontogeny of the hepatic cytochrome enzymes that metabolize lansoprazole and suggest the need for dosage adjustment based on age, especially in the neonatal period.
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Antireflux Surgery
Antireflux surgery is the most common surgical procedure performed by pediatric surgeons in the United States, except for minor procedures (e.g., central intravenous catheter insertion). 62, 63 The Nissen fundoplication is the most commonly used antireflux surgical procedure in pediatric patients with gastroesophageal reflux. 1 It involves suturing folds in the fundus (the uppermost part of the stomach) around the esophagus to repair a hiatal hernia or increase LES pressure and prevent reflux. 13 This surgery was first performed laparoscopically instead of as an open procedure in the mid 1990s, and the popularity of laparoscopic fundoplication has grown dramatically since then. 1, 62 Indications for antireflux surgery include the presence of life-threatening complications from GERD (e.g., aspiration, laryngospasm, apnea), substantial esophageal motility dysfunction, anatomic abnormalities in a neonate, or inadequate response to medical therapy that has been optimized in patients with chronic aspiration, failure to thrive, esophagitis, strictures, or Barrett's esophagitis. 1, 62, 64 Patients who wish to avoid the need for long-term medical therapy because of inconvenience, cost, or adverse effects also may be candidates for surgery.
Outcomes from antireflux surgery usually are favorable, although surgical success rates (i.e., complete relief of GERD symptoms) vary from 57% to 92%. 1 Antireflux surgery produced clinical improvement or allowed a reduction in dosage of bronchodilator and anti-inflammatory medications in 85% of 258 children with severe asthma requiring frequent administration of oral corticosteroids or large dosages of inhaled corticosteroids. 1 Failure of medical antireflux therapy did not preclude a response to antireflux surgery.
The duration of efficacy of fundoplication is limited, and the need for repeat surgery is common. In a survey of adults with GERD, 4% had undergone fundoplication as children (i.e., the efficacy of the procedure diminished over time). 9 Randomized, controlled studies comparing outcomes from surgery with outcomes from medical treatment in pediatric patients with GERD or extra-esophageal complications from GERD are lacking. Surgery typically has been used after medical management fails; however, criteria for surgical patient selection are not always well defined.
1 A meta-analysis was conducted of studies of a total of 8930 children undergoing fundoplication, including 4986 children with neurologic impairment. A substantial percentage (9% to 17%) of the children with neurologic impairment experienced major complications after fundoplication; the relative risk of major complications was 12.8 in these children compared with children without neurologic impairment. The operative failure rate was as high as 25% in patients in whom GERD symptoms had remained uncontrolled despite prior medical therapy, regardless of whether they had neurological impairment (i.e., patients who respond to medical therapy appear to be good surgical candidates). Compared with the population that is not neurologically impaired, the postoperative complication rate was two-to fourfold higher, the morbidity rate was three-to fivefold higher, and the repeat operation rate within 2 years was fourto sixfold higher in patients with neurologic impairment. 10, 64 Studies comparing open fundoplication with laparoscopic fundoplication also are lacking. Patients with comorbid conditions are more likely to undergo open procedures than laparoscopic ones, making comparisons of outcomes from the two types of surgical procedures difficult. Nevertheless, the cost and duration of hospital stay appear to be lower with laparoscopic Nissen fundoplication than with open Nissen fundoplication. 1, 10 The rate of repeat surgery is comparable with the two surgical approaches (7.5% and 9.0% with open procedures and laparoscopic procedures, respectively). However, repeat laparoscopic surgery was required significantly earlier than repeat open fundoplication (after 7 months versus 18 months).
Case Studies CASE 1 SP, a 4-month old Caucasian male infant, presents to the pediatrician's office with his mother, who complains that SP "throws up" after most feedings. SP is fed primarily formula (Enfamil). His mother reports that the vomiting seems effortless. She is unable to quantify the volume of formula that is regurgitated. SP was born after 38 weeks of gestation, weighing 3.5 kg after a normal pregnancy and delivery. SP currently weighs 5.3 kg (about 12 lb), which is normal for his age. On physical examination, SP is a well-developed, well-nourished, alert and oriented infant, with no evidence of failure to thrive. There is no wheezing on chest auscultation. SP's mother reports no episodes of apnea.
SP is a "happy spitter," who requires no diagnostic testing at this time because of the absence of warning signs of a serious condition (e.g., bilious or forceful vomiting, failure to thrive). His mother should be reassured and educated about these warning signs. She should be advised to consider lifestyle modifications (e.g., thickening SP's formula). If the problem does not resolve by the time SP is 18 to 24 months old or if symptoms worsen or change in character, his mother should consult a pediatric gastroenterologist, who will consider performing an esophagogastroduodenoscopy, biopsy, upper GI series, and esophageal pH monitoring (Figure 1 ). Acid-suppressant drug therapy, with or without a prokinetic agent, also may be tried.
CASE 2
PB is a 9-month-old African American female infant who presents to the emergency department with an apparent seizure. Her father reports that after the last formula feeding, PB stopped breathing, her body stiffened, and she arched her back and turned her head to the side. PB's mother noted that PB has experienced episodes of vomiting after feedings and interest in feedings has been low in recent weeks. PB was born prematurely after only 28 weeks of gestation. She has mild bronchopulmonary dysplasia because she required ventilator support for the first 2 weeks of her life. PB's weight is in the fifth percentile adjusted for gestational age, and it has not changed since her 6-month check-up with the pediatrician. On physical examination, PB appears poorly nourished and in distress. Wheezing is noted on chest auscultation.
PB has experienced an ALTE. She also has Sandifer syndrome, an uncommon manifestation of GERD in which a child turns his or her head to the side or arches his or her back to lengthen the lower esophagus, increase pressure at the LES, and decrease reflux. 65, 66 PB should be referred to a pediatric gastroenterologist because her symptoms, failure to gain weight, and history of bronchopulmonary dysplasia suggest that she has GERD. Twenty-four-hour esophageal pH monitoring and a sleep study to monitor PB's heart rate, chest wall movement, nasal airflow, and oxygen saturation as well as esophageal pH should be performed. If GERD is confirmed, thickening of PB's feedings and the use of prokinetic and acid-suppressant drug therapy may be considered.
1
CASE 3
SD is a 10-year-old African American boy with a 2-year history of seasonal allergies and nocturnal and early morning cough. He also has an intermittent sore throat (roughly once a month). As a neonate, SD exhibited excessive regurgitation, which decreased by the age of 12 months and resolved by the time he was 2 years old. SD's mother and grandmother have GERD. SD is in the 75th percentile for height and the 50th percentile for weight. Six months ago SD's pediatrician asked him to try using intranasal and orally inhaled corticosteroids because pulmonary function testing showed mild impairment, suggesting the presence of asthma complicated by seasonal allergies. However, his symptoms improved only minimally after 8 weeks of these therapies. Esophageal pH monitoring was then performed, revealing frequent nocturnal reflux episodes. A subsequent 3-month trial of an inhaled beta 2 -adrenergic agonist and the histamine H 2 -receptor antagonist famotidine (1 mg/kg/day) led to some improvement in the nocturnal cough, but the cough remained a problem. Esophagogastroduodenoscopy was then performed, revealing mild erosive esophagitis.
SD's presentation with nocturnal cough (a possible consequence of bronchoconstriction in patients with asthma), his history of allergies, and the results of pulmonary function testing suggested that the nocturnal cough was due to asthma, which appears to be a contributing factor. Esophageal pH monitoring confirmed suspicions of gastroesophageal reflux, but effective therapy remained elusive until esophagogastroduodenoscopy revealed reflux esophagitis. The histamine H 2 -receptor antagonist was only partially effective in relieving symptoms, and it was ineffective for healing esophagitis. A proton pump inhibitor (e.g., lansoprazole 30 mg once daily) should be substituted for famotidine because it is likely to be more effective in suppressing acid reflux and healing the esophagitis. The orally inhaled corticosteroid and beta 2 -adrenergic agonist should be continued to manage SD's asthma.
Summary
GERD is increasingly common in pediatric patients and can be associated with potentially serious complications, especially in infants and children with neurologic impairment. Early detection and intervention may prevent lifelong GERD complications. The patient presentation in the pediatric age group differs from that in adults. The diagnostic work-up for an infant or child with suspected GERD depends on the age of the patient and the presenting signs and symptoms. Reassurance of the parent or caregiver and lifestyle modifications may suffice for patients with uncomplicated gastroesophageal reflux. Acid-suppressant therapy with a histamine H 2 -receptor antagonist or a proton pump inhibitor is indicated for patients with clinically evident GERD. Drug product selection is based on disease severity, patient age, potential for adverse effects and drug interactions, cost of therapy, and factors that affect patient adherence, including availability of a suitable dosage form, administration frequency, and product taste and texture.
Antireflux surgery usually is reserved for patients with an inadequate response to medical therapy, although patients with life-threatening GERD complications are candidates. The best surgical outcomes are achieved with careful patient selection. Surgery typically results in a favorable outcome, although this outcome may be short lived.
